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Abstract
Objectives To determine which travellers with malaria are at greatest
risk of dying, highlighting factors which can be used to target health
messages to travellers.
Design Observational study based on 20 years of UK national data.
Setting National register of malaria cases.
Participants 25 054 patients notified with Plasmodium falciparum
malaria, of whom 184 died, between 1987 and 2006.
Main outcome measures Comparison between those with falciparum
malaria who died and non-fatal cases, including age, reason for travel,
country of birth, time of year diagnosed, malaria prophylaxis used.
Results Mortality increased steadily with age, with a case fatality of
25/548 (4.6%) in people aged >65 years, adjusted odds ratio 10.68 (95%
confidence interval 6.4 to 17.8), P<0.001 compared with 18–35 year
olds. There were no deaths in the ≤5 year age group. Case fatality was
3.0% (81/2740 cases) in tourists compared with 0.32% (26/8077) in
travellers visiting friends and relatives (adjusted odds ratio 8.2 (5.1 to
13.3), P<0.001). Those born in African countries with endemic malaria
had a case fatality of 0.4% (36/8937) compared with 2.4% (142/5849)
in others (adjusted odds ratio 4.6 (3.1 to 9.9), P<0.001). Case fatality
was particularly high from the Gambia. There was an inverse correlation
in mortality between region of presentation and number of cases seen
in the region (R2=0.72, P<0.001). Most delay in fatal cases was in seeking
care.
Conclusions Most travellers acquiring malaria are of African heritage
visiting friends and relatives. In contrast the risks of dying from malaria
once acquired are highest in the elderly, tourists, and those presenting
in areas in which malaria is seldom seen. Doctors often do not think of
these as high risk groups for malaria; for this reason they are important
groups to target in pre-travel advice.
Introduction
Malaria is a major global infection, causing around 250 million
clinical cases a year.1 It causes around 800 000 deaths a year,
almost all in people living in poverty with limited access to
healthcare, but it also causes avoidable deaths every year from
imported malaria in non-endemic countries, mainly in people
who are otherwise well. Travel to countries where malaria is
endemic is increasing, and most general practitioners and acute
care physicians are involved either in pre-travel advice or in
diagnosing and treating cases on their return. The number of
cases of imported falciparum malaria has increased over the
past four years in the United Kingdom,2 3 with 5774 reported
cases in the period 2007–11. The UK, other European countries,
and the United States also saw increases throughout the 1990s,
which stabilised over the past decade.3-8 Case fatality has
remained stable at around 1%, both in the UK and in other high
income countries.9-11
Migrants frommalaria endemic countries and their descendants
are at particular risk of acquiring malaria and make up over half
of the UK’s imported malaria cases.3 Risk factors for acquiring
malaria may, however, differ from risk factors for dying from
malaria. Previously described risk factors associated with death
from importedmalaria include older age, European origin, travel
to east Africa, failure to take chemoprophylaxis, and delays in
seeking medical care and in the diagnosis and treatment of
suspected malaria.9 10 12 13 Preventing malaria associated deaths
is the ultimate aim in malaria prevention strategies, as those
diagnosed and treated promptly generally make a full recovery.
We reviewed in detail all deaths reported to be caused bymalaria
infection in the UK over a 20 year period and compared them
with all reported cases of malaria over the same period. The UK
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has extensive links with malaria endemic countries and has one
of the highest rates of imported malaria in the developed world.14
We hypothesised that the groups most likely to acquire malaria
may be different from the groups who die from malaria. We
aimed, firstly, to identify factors associated with mortality to
find high risk groups who could be targeted in prevention efforts
by general practitioners and public health campaigns and,
secondly, to learn clinical lessons relevant to the early
identification of malaria in non-endemic countries.
Methods
Malaria is a notifiable infectious disease in the UK, so clinicians
have to report cases by law and all cases of malaria or suspected
malaria are treated free by the National Health Service, including
among non-residents, which reduces financial barriers to
accessing treatment and to being recorded. The Malaria
Reference Laboratory, the national reference laboratory and
part of the UK Health Protection Agency, runs a passive case
detection system; the data collection system has been described
previously.3 When a case is notified (via statutory notification
through local authorities, clinicians sending standardisedmalaria
reports to the Malaria Reference Laboratory, or laboratories
sending blood films for diagnostic verification), the responsible
clinician is contacted and asked to complete a data collection
form, which covers demographic and clinical data. All cases
included are parasitologically confirmed and speciated by
microscopy or histology (and sometimes polymerase chain
reaction) either at the referring hospital or at the Malaria
Reference Laboratory. In most cases the diagnosis is confirmed
by the Malaria Reference Laboratory. This system has been
shown to identify 66% of cases of falciparum malaria in the
UK.15 Reporting methods did not change over the period of the
study.
The notifying laboratory and clinician are requested to provide
further information about patients: personal details (date of
birth, sex, country of birth, country of usual residence), details
of travel (date of arrival in UK, country or region visited,
purpose of travel, duration of visit), prophylaxis taken, and
details of illness (date of onset, date of treatment, and method
of diagnosis). (The data collection sheet is available from the
authors on request.) Where data are not clear they are followed
up at the time by telephone with the referring clinician.
All malaria associated deaths in the UK are separately directly
notified to the Malaria Reference Laboratory by the Office for
National Statistics. Following this, death certificates and
coroner’s reports are obtained where available. In the case of a
death in hospital, clinical and demographic details are requested
from the responsible clinician as above. Cases are
parasitologically confirmed and speciated by the abovemethods
or by autopsy.
Data analysis
Data on malaria cases over the 20 year study period were
prospectively double-entered (by VS and MB) into the Malaria
Reference Laboratorymalaria database. The data were rechecked
for cases (by AS) and deaths (AMC) to identify duplicate or
uncertain data, and any variations manually checked. Data on
cases were entered into dBase IV and subsequently cleaned and
validated using Microsoft Access 10, and deaths were
additionally entered in Microsoft Excel. Data were analysed
using Stata 11 (Statacorp, College Station TX, USA).
Almost all deaths are from falciparummalaria, and our detailed
analysis was therefore restricted to falciparum cases. Bivariate
methods and multivariable logistic regression were conducted
to examine potential risk factors, comparing deaths from
falciparum malaria with the denominator of all imported
falciparummalaria cases to identify risk factors for case fatality.
Unadjusted odds ratios and odds ratios adjusted for these
potentially confounding factors on univariate analysis are
quoted. There were no time series data.
Potential risk factors for death from imported falciparummalaria
were studied by univariate analysis. These were age divided
into groups (≤5, >5–18, >18–35, >35–50, >50–65, and >65
years), sex, tourist versus traveller visiting friends and relatives,
presentation by calendar month, reported use of effectivemalaria
chemoprophylaxis versus reported use of no prophylaxis, birth
in an African country with endemic malaria versus birth
elsewhere, and country and region visited. Countries were
classified as endemic or not endemic for malaria transmission
according to theWorld Health Organization classification.1 The
biologically likely potential confounding factors age, born in a
malaria endemic country, reason for travel, and reported use of
prophylaxis were predetermined to be included as potential
confounding factors in all logistic models. Age results are
presented in clinically relevant groups (such as young adults
>18–35 years old, young children 0–5 years), but adjustment
for confounding in all other multivariable models was performed
using age as a continuous variable. Additionally factors found
to be associated with mortality with a probability value P<0.05
in univariate analysis were introduced into the logistic regression
model to adjust further for confounding. Where data were
missing we used multiple imputation (STATA mi command)
with five imputations. An additional analysis restricted to those
cases with complete data was undertaken to confirm findings;
this restricted analysis led to no change in interpreting these
results (data not shown but available on request).
Cases were analysed by the UK government office region from
where they were reported (North East, North West, Yorkshire
and The Humber, East Midlands, West Midlands, East of
England, London, South East, and South West), Northern
Ireland, Scotland, Wales, and non-UK regions16 to determine
whether mortality was associated with number of cases of
malaria seen locally, and a regression line fitted for log
transformed data comparing mortality rate against number of
cases seen.
This study used routine data collected within the Health
Protection Agency official remit and did not require separate
ethical board approval. Data weremade anonymous for analysis.
Results
Between 1987 and 2006, 191 malaria associated deaths were
reported to the Malaria Reference Laboratory, from a total of
39 302 cases of confirmed malaria in which the outcome was
known. Of the deaths, 184 were associated with P falciparum
infection. There were 25 054 cases of P falciparum malaria,
giving a case fatality of 0.73%. This rate did not change over
the study period,3 and adding year to models made no
appreciable difference so it was excluded. Seven deaths were
associated with non-falciparummalaria, (four from P vivax, and
one each from P ovale and P malariae) among 13 804 cases,
giving a case fatality for non-falciparum malaria of 0.05%.
Among the non-falciparum cases, two patients had severe
pre-existing comorbidities, and one died of splenic rupture.
The remainder of our analysis was performed on the 25 054
cases of falciparum malaria where the outcome was known,
which included 483 cases of mixed infection. Completeness of
data are summarised in table 1⇓; 15 717 had full data, with use
of prophylaxis the most likely to be missing.
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Mortality from P falciparum malaria increased steadily with
increasing age (fig 1⇓ and table 2⇓), with a case fatality of 4.6%
(25/548) in those aged >65 years. The adjusted odds ratio of
dying of malaria was 10.68 (95% confidence intervals 6.4 to
17.8, P<0.001) in those >65 years old compared with the >18–35
year old group. Mortality among infants and children was low,
with no deaths in the ≤5 age group, and a case fatality of 0.33%
(11/3347) in those aged >5–18 years.
Table 3⇓ summarises the risk of death from P falciparum
malaria associated with different factors. Case fatality varied
depending on purpose of visit to a country with endemicmalaria,
from 2.96% (81/2740) in tourists to 0.32% (26/8077) in
travellers visiting friends and relatives (table 4⇓). The adjusted
odds ratio of death associated with tourism compared with
visiting friends and relatives was 8.2 (95% confidence interval
5.1 to 13.3, P<0.001). This remained true even when restricting
the analysis to individuals born in African countries with
endemic malaria; among these individuals, case fatality was
1.6% (3/189) in those visiting for tourism compared with 0.4%
(19/5308) in those visiting friends and relatives (P=0.009).
Those born in an African country with endemic malaria had a
case fatality of 0.4% (36/8937) compared with 2.4% (142/5849)
in those born outside such countries (χ2 test, P<0.001; adjusted
odds ratio of death 4.6 (3.1 to 9.9), P<0.001). There weremarked
regional and national differences, with case fatality of 0.6%
(86/14 174) after visiting west Africa, 1.5% (60/4064) for east
Africa, and 3.3% (12/363) for southern Africa, although these
reduced after adjusting for potential confounding factors such
as reason for travel. Case fatality was particularly high in
individuals visiting the Gambia (3.9%, (28/726)) compared with
any other west African country (0.4% (58/13,448), χ2 test,
P<0.001; adjusted odds ratio of death 4.7 (2.7 to 8.1), P<0.001).
Restricting the analysis to tourists increased this difference,
with a case fatality of 6.0% (20/333) for cases from the Gambia
compared with 1.4% (8/565) for tourists visiting the rest of west
Africa (χ2, P<0.001).
There was a striking seasonal peak in deaths from imported P
falciparum malaria, with a case fatality of 2.6% (49/1922) in
those notified in December compared with 0.6% across all other
months (135/23 132) (χ2 test, P<0.001) (fig 2⇓), meaning that
over a quarter of deaths occurred in cases notified in December.
The peak for number of imported cases is September.3 In the
December cases 25.0% (11/44) of individuals died at home,
compared with 17.4% (21/121) in other months (difference not
significant). More tourists (9.3%) than those visiting friends
and relatives (5.4%) were notified in December, although the
greater mortality in December remained after correcting for
purpose of visit as well as other factors (table 3⇓).
There was a clear trend in mortality based on the UK
government office region where the patient presented, which
was inversely correlated with number of cases seen (fig 3⇓)
(linear regression R2=0.72, P<0.001). The highest case fatality
of 8.4%was in a region where only 119 patients were seen, with
10 deaths; the lowest case fatality (0.3%) was in the region
where most cases were seen, with 15 993 patients seen and 50
deaths (adjusted odds ratio 18.2 (8.6 to 38.3), P<0.001).
Restricting the analysis only to tourists, case fatality was 6/20
(30%) among cases presenting in the region where fewest cases
were seen, compared with 7/979 (0.7%) in the region where
most cases were seen (χ2 test, P<0.001).
Data on reported chemoprophylaxis was inevitably limited and
has to be treated with caution in fatal cases for reasons of
reporting bias. Where the data were available, 35.8% (5711/15
933) individuals reported taking prophylaxis against malaria
infection, and, among these, 5.7% (903/15 933) reported taking
one of the three regimens effective in Africa (mefloquine,
atovaquone-proguanil, or doxycycline). Of those taking either
no prophylaxis or an ineffective regimen, 64.2% took no
prophylaxis, 6.7% took chloroquine, 15.4% took chloroquine
and proguanil, 4.1% proguanil, 0.7% pyrimethamine, and 3.5%
another regimen. Among individuals not born in an African
country with endemic malaria, case fatality was 0.6% (3/509)
among those who reported taking effective prophylaxis, 1.4%
(42/3046) among those who took any prophylaxis, and 3.5%
(80/2304) among those who took no prophylaxis.
Median time intervals in fatal cases are summarised in fig 4⇓.
Among the fatal cases, 75.1% of deaths were in hospital, 18.1%
at home, and 3.4% in an ambulance, and the median percentage
of red blood cells parasitised was 8.5% (interquartile range
1–25%). These data were available only in the fatal cases.
Discussion
This study shows that risk factors for dying from imported
falciparum malaria in the UK are different from those for first
acquiring the infection, and highlights groups of travellers who
should be targeted for pre-travel health advice when they seek
medical care. Those visiting friends and relatives in countries
with endemic malaria make up the majority of cases of
falciparum malaria in the UK, but the risks of this group dying
from malaria are much smaller than for other travellers,3 with
most deaths occurring in tourists. Older age is strongly
associated with mortality, and, in contrast to cases in Africa,
mortality in children is minimal. There were both seasonal and
geographical risks in the UK for dying from malaria, with a
clear peak in December, and consistently higher risks of dying
for patients presenting in UK regions where malaria is less
regularly seen and treated. Travellers to the Gambia, a popular
destination for winter sun, were at particular risk. Most delays
occurred before presentation to medical services. These findings
are biologically plausible (see discussion below), compatible
with other data, and have implications for targeting pre-travel
health messages and treatment when travellers return.
The effect of previous exposure on mortality
Most cases of malaria in the UK are in individuals born in
African countries with endemic malaria who are returning from
visiting friends and relatives. Public health efforts have therefore
concentrated on encouraging such people to take up
chemoprophylaxis.3 This remains an important message and is
backed up by European data showing that rates of
chemoprophylaxis use are low and of malaria are high in this
group.17 18 However, our study shows that, both in absolute
numbers and in relative risk, tourists and those born outside
African countries with endemic malaria are more likely to die
once malaria is acquired. These data complement other studies
from Europe and case series in the UK.4 12 19 20
There are several possible reasons for these findings, some
biological and some behavioural. Those exposed to malaria in
childhood develop immunity to severe malaria, with more
protection the higher the degree of exposure; although they may
still develop symptomatic infection, the risk of complications
and death is greatly reduced.21 This protection is incomplete,
and wanes with time, but studies on imported malaria and in
areas where malaria occurs in occasional epidemics suggest that
some degree of protection continues for a prolonged
period.4 12 19 22 Other factors may also play a role; some genetic
polymorphisms more prevalent in regions of malaria
transmission are associated with protection from severe
malaria.23 24
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Immunity to malaria is however unlikely to be the full reason,
as analyses restricted to those born in the UK (second or third
generation migrants) or to tourists compared with those visiting
friends and relatives when born in Africa still show significant
differences. It is likely, although not possible to test with this
study design, that differences in health seeking make up at least
some of the difference. Those with an African heritage and
staying with African families may be exposed to an
understanding that malaria is common and dangerous, and may
know the symptoms of early disease; malaria is, if anything,
overdiagnosed as a cause of fever in medical practice in west
and east Africa.25-27Conversely most tourists to Africa (and even
their healthcare providers) may be unaware that several attacks
of falciparum malaria a year are typical in residents living in
highly endemic areas (considerably more common than
influenza in the United Kingdom), and that around 20% of fevers
in those returning from Africa to the UK are due to malaria.27
The effect of age on mortality
Increasing age was strongly and independently associated with
an increasing risk of death from malaria, and there was no
evidence of the high case fatality seen in children in malaria
endemic countries. These data are supported by previous reports
of increased case fatality11 28 29 and higher levels of parasitaemia
in elderly people.30 The mechanism is unclear, but it is unlikely
that it is explained solely by increasing comorbidities in older
age groups, as our study and others9 11 show a continuous
increase in case fatality from childhood upwards.
Our findings in children are also in keeping with a smaller
prospective study of children in the UK, which found a
substantial number of severe cases but no deaths.31 A low case
fatality in children has been documented in settings with low
levels of endemic malaria, such as in the highlands of Kenya,32
KwaZulu-Natal,33 and Ceylon (Sri Lanka),34 and also in
non-immune individuals migrating to an Indonesian island
hyper-endemic for malaria transmission.35 These data are
compatible with an explanation that the reason for highmortality
from childhood malaria in Africa is limited access to health
services.
The effect of region within Africa, season and
number of cases seen in regions onmortality
The higher case fatality in visitors to east Africa compared with
west Africa was accounted for by a greater proportion of tourists
visiting east Africa. The exception in west Africa is the Gambia,
which had a strikingly high case fatality. Visitors to this country
typically have other risk factors, including being tourists, older,
and born in the UK, but, even after adjustment for these factors,
the odds ratio remained high. This previously reported high case
fatality36 37may reflect the predominance of Europeans travelling
on package holidays, with low levels of use of chemoprophylaxis
and little awareness of the risk of malaria on return.
Case fatality had a marked seasonal variation independent of
peaks in the numbers of cases, which occurred in September
and January (fig 2⇓).3Higher case fatality occurs over the winter
in several conditions; peaks in all cause and cardiac mortality
occurred on Christmas Day and New Year’s Day in a study of
all deaths recorded in the United States between 1973 and
2001,38 and all cause mortality peaked on New Year’s Day in
north east England.39 Delayed presentation to hospital, lower
levels of hospital staffing over the holiday period, and delays
in communication of the malaria diagnosis from laboratory to
physicianmay be contributory factors. Other possibilities include
initial misdiagnosis of a febrile illness as influenza-like illness,
and the different demographics of travellers who travel in search
of “winter sun.” The non-significant increase in the proportion
of deaths occurring at home during this month may reflect
delayed presentation to medical services during this time.
There was an inverse correlation between the number of cases
seen per UK region and case fatality. This is partly explained
by the younger age and higher proportion of African nationals
presenting in London. However, after adjusting for confounding
factors, we found the odds of dying from malaria remained
much higher in those presenting in regions where fewer cases
of malaria were seen, and the increase in case fatality with
decreasing number of cases in fig 3⇓ is striking. Less awareness
of malaria among friends and neighbours may lead to travellers
being less likely to seek advice from doctors before travel, or
to recognise that malaria is a possibility if they experience a
fever on return. Equally, in regions where travel to malarious
areas is less common, general practices advising on prophylaxis
and doctors seeing febrile returned travellers may be less aware
of the risk of malaria, and this is an area where public health
advice and medical training should be targeted.
Prophylaxis and delay to treatment
The use of effective prophylaxis was associated with lower risk
of death from malaria in those not born in an African country
with endemic malaria. There was no association between
prophylaxis and case fatality in those born in African countries
with endemic malaria. These data should, however, not be
over-interpreted as a combination of reporting bias and
incomplete data make it difficult to reach firm conclusions.
Delays in presentation, diagnosis, and administration of effective
treatment are critical in contributing to deaths frommalaria.7 10 40
The median delay from the development of symptoms to the
diagnosis of malaria in our study is similar to the reported time
intervals of 4–8.5 days in other studies.12 19 Reassuringly, our
results suggest that treatment was usually initiated on the day
of diagnosis, althoughwewere unable to comment on individual
regimens. These data also suggest that most patients who died
presented late in the course of their illness, since the time
interval between diagnosis and death was short. This suggestion
is supported by the observation that 26% of individuals died
either at home or in an ambulance. Reducing delays to
presentation may be the single most important factor that could
reduce mortality, although we are unable to test this from these
data. There was no significant difference between time from
onset of symptoms to diagnosis of malaria, from diagnosis to
initiation of treatment, and from diagnosis to death, but numbers
were small (data not shown). Data on delays were only available
in fatal cases, so associations with mortality cannot be directly
tested.
Potential limitations of the study
There are limitations associated with the use of national data.
Under-reporting is inevitable in a passive case detection system,
although capture-recapture data suggest that levels of reporting
are high.15 The reporting of deaths known to be due to malaria
is likely to be more complete than that of surviving cases, as
deaths may also be reported via coroners as well as by clinical
staff, althoughmalaria may not have been suspected in all people
who died at home without autopsy. Data on certain factors, such
as those relating to delay in presentation, were available only
for fatal cases, so their contribution to mortality cannot be
directly assessed. Certain data, in particular the use of
chemoprophylaxis, are likely to be associated with considerable
recall bias in fatal cases. Lastly, although we adjusted for
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important potential confounding factors we identified, we cannot
exclude the presence of residual confounding. It seems unlikely,
however, that the clear associations of case fatality with age,
reason for travel, being born in a non-endemic country, the
calendar month, and the number of cases seen per region could
be largely explained by residual confounding.
Implications for practice
These data describe two different groups of people—ethnic
Africans (mainly of west African heritage), who travel mainly
to west Africa to visit friends and relatives and bear the main
burden of morbidity from falciparum malaria, and Europeans,
who travel as tourists to east and southern Africa and to the
Gambia in west Africa and have a higher case fatality.
Additionally, case fatality was higher in those presenting in
December, and in those presenting in UK regions where malaria
is less often seen.
Our results suggest that certain groups may particularly benefit
from interventions to reduce the mortality from imported
malaria, in particular pre-travel advice to encourage prompt
presentation to healthcare facilities on the development of a
febrile illness as well as stressing the need for antimalaria
measures and chemoprophylaxis. These groups include the older
traveller, travellers born in countries not endemic for malaria,
and those travelling on “winter sun” holidays, in particular to
the Gambia. It should not be forgotten, however, that individuals
born in African countries with endemic malaria still bear the
brunt of morbidity from imported malaria cases, so the
importance of pre-travel advice and education in this group
remains. Doctors in the UK advising patients who seldom travel
but take a holiday to Africa must make them aware that malaria
is very common, potentially fatal, may start initially with mild
symptoms and needs early diagnosis.41Older visitors to malaria
endemic countries, especially older tourists, are in particular
need of targeting for pre-travel advice, both to take prophylaxis
and to seek care early if unwell on return.
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What is already known on this topic
Falciparum malaria is a common cause of fever in travellers returning to the UK from Africa
Individuals whose families originate from malaria endemic countries visiting friends and relatives are at greatest risk of importing malaria
infection to the UK
Most deaths from malaria in endemic countries are in children, but deaths from malaria in children are rare in the UK
What this study adds
Holiday makers and tourists are at greatest risk of dying from malaria in the UK
Mortality from malaria increases steadily with age in the UK
Presentation in the month of December and to UK regions where malaria is rarely seen are associated with marked increase in mortality
Elderly travellers in particular need to be targeted for pre-travel advice
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Tables
Table 1| Completeness of data for notified cases of Plasmodium falciparum malaria in UK between 1987 and 2006
No (%) of cases with complete dataFactor studied
All cases of P falciparum malaria (n=25 054)
24 244 (97)Age
23 653 (94)Sex
14 787 (59)Country of birth
21 856 (87)Country visited
17 252 (69)Purpose of travel
25 054 (100)Month reported
24 751 (99)UK county where case reported
15 933 (64)Use of malaria prophylaxis
All deaths from P falciparum malaria (n=184)
135 (73)Time from arrival in UK to onset of symptoms
142 (77)Time from arrival in UK to death
146 (79)Time from onset of symptoms to diagnosis
92 (50)Time from diagnosis to starting specific treatment
161 (88)Time from diagnosis to death
177 (96)Location of death
150 (82)Receipt of specific treatment before death
61 (33)Percentage of red blood cells parasitised
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Table 2| Risk of death from imported P falciparum malaria in UK between 1987 and 2006 by age
Odds ratio (95% CI) of death
Age group (years) P valueAdjusted*P valueCrude
———0 deaths0–5
0.540.81 (0.4 to 1.6)0.360.73 (0.4 to 1.4)>5–18
—1.0 (reference group)—1.0 (reference group)>18–35
0.021.63 (1.1 to 2.5)0.071.49 (0.97 to 2.3)>35–50
<0.0014.6 (3.1 to 6.9)<0.0014.6 (3.1 to 6.8)>50–65
<0.00110.68 (6.4 to 17.8)<0.00110.66 (6.5 to 17.6)>65
*Adjusted for risk factors listed in table 3.
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Table 3| Factors other than age associated with risk of death from imported P falciparum malaria in UK between 1987 and 2006
Odds ratio (95% CI) of death
No (%) of fatal casesRisk factor P valueAdjusted*P valueCrude
Purpose of visit to country with endemic malaria:
<0.0018.2 (5.1 to 13.3)<0.0019.4 (6.1 to 14.7)81/2740 (2.96)Tourism
26/8077 (0.32)Visiting friends and relatives
UK region where disease presented:
<0.00118.2 (8.6 to 38.3)<0.00129.3 (14.5 to 59.2)10/119 (8.40)Where least malaria is seen
50/15 993 (0.31)Where most malaria is seen
Calendar month of presentation:
<0.0013.7 (2.6 to 5.2)<0.0014.5 (3.2 to 6.2)49/1922 (2.55)December
135/23 132 (0.58)All other months
Reported use of effective prophylaxis:
0.132.0 (0.81 to 4.9)0.2201.8 (0.7 to 4.3)99/10 222 (0.97)No
5/903 (0.55)Yes
Birth in African country with endemic malaria:
<0.0014.6 (3.1 to 9.9)<0.0016.2 (4.3 to 8.9)142/5849 (2.43)No
36/8937 (0.40)Yes
*Adjusted for age (continuous) and for other listed risk factors.
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Table 4| Purpose of visiting a country with endemic malaria among cases of imported P falciparum malaria in UK between 1987 and 2006
and associated case fatality
No (%) of fatal casesPurpose of travel
81/2740 (2.96)Tourist from UK visiting malaria endemic country
17/3841 (0.44)Visiting UK from malaria endemic country
26/8077 (0.32)Visiting friends and relatives in malaria endemic country
60/10 396 (0.58)Other or unstated
184/25 054 (0.73)Total
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Figures
Fig 1 Mortality from imported P falciparum malaria in UK between 1987 and 2006 by age
Fig 2 Mortality from imported P falciparum malaria in UK between 1987 and 2006 by month of notification of illness
Fig 3 Mortality from imported P falciparum malaria as a function of number of cases seen in a UK region between 1987
and 2006 (R2=0.67, P<0.001)
Fig 4 Relevant time intervals in fatal cases of imported P falciparum malaria in the UK between 1987 and 2006
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